The test will allow the simultaneous detection of Flu-A, Flu-B, RSV and Covid-19. Credit: fernandozhiminaicela from pixabay.

US-based Domus Diagnostics has secured funding from the National Institutes of Health (NIH) to support the development of its at-home point-of-care nucleic acid amplification and detection test.

The molecular test is being developed for the simultaneous detection of Flu-A, Flu-B, respiratory syncytial virus (RSV) and Covid-19.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The company has been awarded up to $2.4m under NIH’s Rapid Acceleration of Diagnostics Tech programme to advance the validation and scaling of its testing platform for clinical trial readiness.

The company is engaged in the development of a cost-effective, high-performance nucleic acid amplification and detection test, which can be marketed at a lower price than current antigen tests in the US.

Using the Domus test, a clinician or patient can easily obtain a sample by swabbing each nostril. The collected sample is then placed in a collection chamber within a card and results can be viewed after 30 minutes.

See Also:

Furthermore, Domus technology operates without the need for instruments, electricity or batteries.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Domus Diagnostics president and CEO Paul Chapman said: “Our mission has always been to develop a lower-cost, accessible and highly accurate testing solution to dramatically expand use and improve outcomes around the world.

“The NIH award will enable us to take a major next step toward validating our platform and moving into clinical trials.”

The Domus Diagnostics platform is a zero-power platform which will help create new devices for precise, efficient and user-friendly infectious disease testing.

The devices can be used for testing at home, in community testing facilities or in doctors’ offices.

According to the company, the devices will serve as an affordable and accessible global option to test infectious diseases.